CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleotides (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.
Murad
Yanal M
YM
Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Durham, NC 27710, USA. yanal.murad@duke.edu
Clay
Timothy M
TM
Lyerly
H Kim
HK
Morse
Michael A
MA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D051217:Toll-Like Receptor 9 / Q000819:agonists*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D009838:Oligodeoxyribonucleotides; C483020:ProMune; D051217:Toll-Like Receptor 9